


***31st Annual Prostate Cancer Foundation
Scientific Retreat***

October 24 - 26, 2024

***Omni La Costa Resort
Carlsbad, California***



AGENDA

Thursday, October 24, 2024

GENERAL SESSIONS

Location: Costa Del Sol Ballroom

8:00 AM

Registration

Costa Del Sol Foyer

Welcome & Opening Remarks

1:00 PM - 1:05 PM

Howard Soule
Prostate Cancer Foundation
Andrea Miyahira
Prostate Cancer Foundation

Session 1: Tumor Metabolism

1:05 PM - 2:25 PM

Moderator: Andrew Goldstein
University of California, Los Angeles

1:05 PM - 1:20 PM

Prostate Lineage-Specific Metabolism Governs Luminal Differentiation and Response to Antiandrogen Treatment

Andrew Goldstein
University of California, Los Angeles

1:20 PM - 1:25 PM

Discussion

1:25 PM - 1:40 PM

Dietary Target Therapy and Oxidative Death

Lloyd Trotman
Cold Spring Harbor Laboratory

1:40 PM - 1:45 PM

Discussion

1:45 PM - 2:00 PM

In Vivo Nutrient Tracing and Targeted Metabolic Vulnerabilities in Rare Cancers

Heather Christofk
University of California, Los Angeles

2:00 PM - 2:05 PM

Discussion

Thursday, October 24, 2024

- 2:05 PM - 2:20 PM ***Whole-Food Plant-Based Diet to Control Weight and Metabo-Inflammation in Overweight/Obese Men With Prostate Cancer Receiving ADT***
David Nanus
Weill Cornell Medicine
- 2:20 PM - 2:25 PM **Discussion**

Session 2: Genomics of Prostate Cancer Racial Disparities

2:25 PM - 3:45 PM

Moderator: Vanessa M. Hayes
The University of Sydney, Australia

- 2:25 PM - 2:40 PM ***African-Ancestry Associated Genomic Differences in Cancer***
Jian Carrot-Zhang
Memorial Sloan Kettering Cancer Center
- 2:40 PM - 2:45 PM **Discussion**
- 2:45 PM - 3:00 PM ***The Interplay of Epigenome and Environmental Factors in Prostate Cancer Disparities***
Bernard Kwabi-Addo
Howard University College of Medicine
- 3:00 PM - 3:05 PM **Discussion**
- 3:05 PM - 3:20 PM ***Utilizing a Pan-African Approach to Reduce Prostate Cancer Disparities***
Clayton Yates
John Hopkins School of Medicine
- 3:20 PM - 3:25 PM **Discussion**
- 3:25 PM - 3:40 PM ***Prostate Cancer Genomic Disparities Across the African Diaspora***
Vanessa M. Hayes
The University of Sydney, Australia
- 3:40 PM - 3:45 PM **Discussion**

Session 3: The Tumor Immune Microenvironment: Reprogramming Macrophages

3:45 PM - 4:45 PM

Moderator: Jelani Zarif
Johns Hopkins University

- 3:45 PM - 4:00 PM ***Metabolic Reprogramming of Tumor-associated Macrophages using Glutamine Antagonist JHU083 Drives Tumor Immunity in Myeloid-Rich Prostate and Bladder Cancer Tumors***
Jelani Zarif
Johns Hopkins University
- 4:00 PM - 4:05 PM **Discussion**

Thursday, October 24, 2024

- 4:05 PM - 4:20 PM ***Investigations in the Tumor Microenvironment Pave the Way for New Cell Therapy Approaches***
Rosie Kaplan
National Cancer Institute
- 4:20 PM - 4:25 PM **Discussion**
- 4:25 PM - 4:40 PM ***Multimodal Pro-Inflammatory Conversion of Tumor Myeloid Stroma by STING Activation***
Michael Curran
University of Texas MD Anderson Cancer Center
- 4:40 PM - 4:45 PM **Discussion**

Session 4: High Impact Clinical Trials for Patients with Prostate Cancer

4:45 PM - 5:45 PM

Moderator: Howard Soule
Prostate Cancer Foundation

- 4:45 PM - 4:55 PM ***Prostate Cancer UK's TRANSFORM Programme: A Randomised Clinical Trial of Prostate Cancer Screening and a National Prostate Cancer Bio-Digital Twin to Power Biomarker Discovery, Innovation and Validation***
Matthew Hobbs
Prostate Cancer UK
- 4:55 PM - 5:00 PM ***Rakesh Heer***
Imperial College London, UK
- 4:55 PM - 5:00 PM **Discussion**
- 5:00 PM - 5:10 PM ***Abiraterone Decanoate (PRL-02/ASP5541): A Precision Approach to Androgen Biosynthesis Inhibition***
William Moore
Astellas
- 5:10 PM - 5:15 PM **Discussion**
- 5:15 PM - 5:25 PM ***Metacure: Multi-Arm Multimodality Therapy for Very High Risk Localized and Low Volume Metastatic Prostatic Adenocarcinoma***
Howard Scher
Memorial Sloan Kettering Cancer Center
- 5:25 PM - 5:30 PM **Discussion**
- 5:30 PM - 5:40 PM ***BMS-986365 (CC-94676), a Dual Androgen Receptor Ligand-Directed Degradar and Antagonist, for the Treatment of Advanced Prostate Cancer***
Vivek Arora
Bristol Myers Squibb
- 5:40 PM - 5:45 PM **Discussion**

Thursday, October 24, 2024

- 5:45 PM - 5:55 PM ***Efficacy and Safety of Darolutamide Plus Androgen-Deprivation Therapy (ADT) in Patients with Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) from the Phase 3 ARANOTE Trial***
Rana McKay
University of California, San Diego
- 5:55 PM - 6:00 PM **Discussion**
- 6:00 PM - 6:10 PM ***A Randomized Multicenter Open-Label Phase III Trial Comparing Enzalutamide vs a Combination of Radium 223 and Enzalutamide in Asymptomatic or Mildly Symptomatic Patients with Bone Metastatic mCRPC***
Andrey Soares
Hospital Albert Einstein, Sao Paulo, Brazil and Latin American Cooperative Oncology Group - LACOG, Porto Alegre, Brazil
- 6:10 PM - 6:15 PM **Discussion**

Dinner

6:30 PM - 7:30 PM

Dinner Location: Costa Del Sol Patio

Poster Session and Dessert

7:30 PM - 10:30 PM

Poster Session and Dessert Location: Costa De La Luna Ballroom

Friday, October 25, 2024

6:00 AM - 6:45 AM Breakfast

Location: Costa Del Sol Patio

6:45 AM - 7:00 AM Move to Session

GENERAL SESSIONS

Location: Costa Del Sol Ballroom

Session 5: Can AI Drive Innovation in Cancer Research and Cancer Care?

7:00 AM - 8:00 AM

Moderator: Bissan Al-Lazikani

The University of Texas MD Anderson Cancer Center

7:00 AM - 7:15 AM *Using AI to Predict Patient Drug Responses and Outcomes from Preclinical Data*

Katie Campbell

Broad and MIT

7:15 AM - 7:20 AM Discussion

7:20 AM - 7:35 AM *Digital Twins for Drug Development to Individualized Therapy*

Bissan Al-Lazikani

The University of Texas MD Anderson Cancer Center

7:35 AM - 7:40 AM Discussion

7:40 AM - 7:55 AM *Using Large Language Models to Improve Representation of Patients' Experience with Cancer and its Treatment – Insights from the Lancet Commission on Cancer and Health Systems*

André Pfob

Heidelberg University Hospital

7:55 AM - 8:00 AM Discussion

Friday, October 25, 2024

SPECIAL LECTURE

8:00 AM - 8:20 AM

Lessons From 20 Years of STAMPEDE

Nicholas James

The Institute of Cancer Research, UK

Introduced by Gerhardt Attard

University College London Cancer Institute, UK

8:20 AM - 8:25 AM

Discussion

Session 6: The PCF-VA Partnership: Bringing Precision Medicine to Veterans

8:25 AM - 9:20 AM

Moderator: Isla Garraway

University of California, Los Angeles; Greater Los Angeles VA Healthcare System

8:25 AM - 8:40 AM

VA MAPP: Multilevel Data and Biospecimen Repository for Unprecedented Discovery and Validation

Isla Garraway

University of California, Los Angeles; Greater Los Angeles VA Healthcare System

Kara Maxwell

University of Pennsylvania; Corporal Michael J. Crescenz VA Medical Center

8:40 AM - 8:55 AM

VA Studies Led by Young Investigators: Landscape of Somatic Prostate Cancer Alterations in the VA population

Luca Valle

University of California, Los Angeles; Greater Los Angeles VA Healthcare System

VA Studies Led by Young Investigators: Treatment and Outcomes of mHSPC in Veterans: Initial use of Tumor Suppressor Genes for Prognosis

Martin Schoen

Saint Louis University; St. Louis Veterans Affairs Medical Center

Friday, October 25, 2024

8:55 AM - 9:10 AM

Full Spectrum VA Clinical Studies from SOLAR to AI

Nicholas Nickols

University of California, Los Angeles; Greater Los Angeles VA Healthcare System

Matthew Rettig

University of California, Los Angeles; Greater Los Angeles VA Healthcare System

9:10 AM - 9:20 AM

Session Discussion

SPECIAL ANNOUNCEMENT

9:20 AM - 9:25 AM

The PCF Gender Equity Networking Initiative

Claire Fletcher

Imperial College London, UK

Introduced by Andrea Miyahira

Prostate Cancer Foundation

9:25 AM - 9:30 AM

Discussion

Dr. Felix Feng Special Lecture

9:30 AM - 9:55 AM

Science and Friendship

Himisha Beltran

Dana-Farber Cancer Institute

Introduction by Amina Zoubeidi

University of British Columbia

9:55 AM - 10:00 AM

Discussion

Friday, October 25, 2024

SPECIAL LECTURE

10:00 AM - 10:30 AM

The JnJ Prostate Cancer Portfolio

John Reed

Johnson & Johnson Innovative Medicine

Introduced by Charles Drake

Johnson & Johnson Innovative Medicine

10:30 AM - 10:35 AM

Discussion

SPECIAL LECTURE

10:35 AM - 10:55 AM

"We're Not in Kansas Anymore" - Cancer Lessons from the Wizard of Oz

Kenneth Pienta

Johns Hopkins University

Introduced by Howard Soule

Prostate Cancer Foundation

10:55 AM - 11:00 AM

Discussion

Friday, October 25, 2024

KEYNOTE ADDRESS

11:00 AM - 12:00 PM

Michael Milken

Founder and Chairman
Prostate Cancer Foundation

Introduced by Stuart Holden

Prostate Cancer Foundation; University of California, Los Angeles

Group Photo

12:00 PM - 12:10 PM

Location: Costa Del Sol Foyer

Lunch

12:10 PM - 1:00 PM

Location: Costa Del Sol Patio

1:00 PM - 1:15 PM Move to Session

Location: Costa Del Sol Ballroom

Friday, October 25, 2024

SPECIAL LECTURE

1:15 PM - 1:30 PM

**Germline DNA Damage Repair Variants and Prognosis of Patients
with High-Risk or Metastatic Prostate Cancer**

Konrad Stopsack

Massachusetts General Hospital; Harvard T.H. Chan School of Public Health

Introduced by Philip Kantoff

Convergent Therapeutics; Memorial Sloan Kettering Cancer Center;
Harvard Medical School; Dana-Farber Cancer Center

1:30 PM - 1:35 PM

Discussion

Session 7: Next Generation Theranostics

1:35 PM - 3:00 PM

Moderator: Michael Hofman

Peter MacCallum Cancer Centre, Australia

1:35 PM - 1:40 PM

Introduction

Michael Hofman

Peter MacCallum Cancer Centre, Australia

1:40 PM - 1:55 PM

PSMA: What's New in 2024?

Louise Emmett

The University of New South Wales, Australia

1:55 PM - 2:00 PM

Discussion

2:00 PM - 2:15 PM

New Atoms

Jason Lewis

Memorial Sloan Kettering Cancer Center

2:15 PM - 2:20 PM

Discussion

2:20 PM - 2:35 PM

New Theranostic Targets

Andrew Armstrong

Duke University

2:35 PM - 2:40 PM

Discussion

Friday, October 25, 2024

- 2:40 PM - 2:55 PM ***Trials in Action: What's Hot?***
James Buteau
Peter MacCallum Cancer Centre, Australia
- 2:55 PM - 3:00 PM **Discussion**

Session 8: Next Generation Cancer Immunotherapies

3:00 PM - 4:20 PM

Moderator: Saul Priceman
University of Southern California

- 3:00 PM - 3:15 PM ***Novel CAR T Cells for Prostate Cancer***
Saul Priceman
University of Southern California
- 3:15 PM - 3:20 PM **Discussion**
- 3:20 PM - 3:35 PM ***Novel Incorporation of Transgenic Cytokines into Immunotherapeutic Strategies***
Rosa Nguyen
National Cancer Institute
- 3:35 PM - 3:40 PM **Discussion**
- 3:40 PM - 3:55 PM ***Cancer Immunotherapy Using Multiplex Non-Viral Genome Engineered Immune Effector Cells***
Branden Moriarity
University of Minnesota
- 3:55 PM - 4:00 PM **Discussion**
- 4:00 PM - 4:15 PM ***Next Generation CAR T cells for Patients with Cancer***
Marcela Maus
Massachusetts General Hospital
- 4:15 PM - 4:20 PM **Discussion**

Session 9: Advanced Molecular Biology of Lethal Prostate Cancer

4:20 PM - 5:00 PM

Moderator: Joaquin Mateo
Vall d'Hebron Institute of Oncology, Spain

- 4:20 PM - 4:35 PM ***AR-V7 Expression in AR Mutated and Non-Mutated mCRPC***
Alec Paschalis
Institute of Cancer Research, UK
- 4:35 PM - 4:40 PM **Discussion**

Friday, October 25, 2024

4:40 PM - 4:55 PM ***Minor Intron Splicing in the Pathogenesis of Lethal Prostate Cancer***
Mark A. Rubin

University of Bern and Inselspital, Switzerland

4:55 PM - 5:00 PM **Discussion**

5:00 PM - 7:00 PM Break

Dinner, Awards Ceremony, and Special Lecture

7:00 PM - 10:00 PM

Location: Costa Del Sol Ballroom

SPECIAL ANNOUNCEMENT

A Data-Exchange Program for a Novel GRIPR-PET Tracer

7:45 PM - 7:55 PM

Bela Denes

Lantheus

Introduced by Howard Soule

Prostate Cancer Foundation

PCF Awards Ceremony

8:15 PM - 9:30 PM

2024 HBCU-PCF Recognition Award

2024 PCF Young Investigator Awards

2024 PCF Challenge Awards

2023 PCF Challenge Awards

2024 PCF-Pfizer Visiting Professorship Awards

Saturday, October 26, 2024

6:00 AM - 6:45 AM Breakfast

Location: Costa Del Sol Patio

6:45 AM - 7:00 AM Move to Session

GENERAL SESSIONS

Location: Costa Del Sol Ballroom

Session 10: Clinical Survivorship 2.0: Metabolic Effects in Survivorship Biology

7:00 AM - 8:05 AM

Moderator: Alicia Morgans

Dana-Farber Cancer Institute

7:00 AM - 7:05 AM *Introduction*

Alicia Morgans

Dana-Farber Cancer Institute

7:05 AM - 7:20 AM *Metabolism Effects in Response, Resistance, and Complications of Treatment*

Nima Sharifi

University of Miami

7:20 AM - 7:25 AM Discussion

7:25 AM - 7:40 AM *Exercise and Dietary Impacts on Prostate Cancer Outcomes*

Stacey Kenfield

University of California, San Francisco

7:40 AM - 7:45 AM Discussion

7:45 AM - 8:00 AM *The Genetic Basis of QOL from CHAARTED*

Daniel Sentana

Dana-Farber Cancer Institute

8:00 AM - 8:05 AM Discussion

Saturday, October 26, 2024

SPECIAL LECTURE

8:05 AM - 8:20 AM

Lessons on the Mechanisms of Plasticity from Small Cell Lung Cancer

Triparna Sen

Icahn School of Medicine at Mount Sinai

Introduced by Andrea Miyahira

Prostate Cancer Foundation

8:20 AM - 8:25 AM

Discussion

Session 11: Targeting Post-Transcriptional Gene Regulation in Prostate Cancer

8:25 AM - 9:45 AM

Moderator: Duygu Kuzuoglu Ozturk

University of California, San Francisco

8:25 AM - 8:40 AM

Small Molecule RNA Therapeutics to Target Prostate Cancer

Duygu Kuzuoglu Ozturk

University of California, San Francisco

8:40 AM - 8:45 AM

Discussion

8:45 AM - 9:00 AM

The RNA Components of the Translational Machinery in Prostate Cancer Pathogenesis

Andrew Hsieh

Fred Hutchison Cancer Center

9:00 AM - 9:05 AM

Discussion

9:05 AM - 9:20 AM

An RNA-Dependent Positive Feedback Loop Drives Malignant Ribosome Biogenesis

Faraz Mardakheh

University of Oxford, UK

9:20 AM - 9:25 AM

Discussion

Saturday, October 26, 2024

9:25 AM - 9:40 AM ***Regulation of Ribosome Biogenesis by Noncoding RNAs in Senescence and Cancer***

Josh Mendell
UT Southwestern

9:40 AM - 9:45 AM **Discussion**

Session 12: New Biotechnologies in Genomic Medicine

9:45 AM - 10:25 AM

Moderator: Howard Soule
Prostate Cancer Foundation

9:45 AM - 10:00 AM ***Looking Back to Look Forward: Using Genomics and Electronic Health Records to Optimize Current & Future Clinical Decisions***

Ryon Graf
Foundation Medicine

10:00 AM - 10:05 AM **Discussion**

10:05 AM - 10:20 AM ***Immune System Profiling - Extracting Dynamic Response Data from the Peripheral Blood***

Michael F. Goldberg
BostonGene

10:20 AM - 10:25 AM **Discussion**

Session 13: Advances in "In Vivo" Cell Therapy Platforms and Novel Small Molecule Cancer Therapies

10:25 AM - 11:50 AM

Moderator: Marco Gottardis
Gottardisbiotech LLC

10:25 AM - 10:30 AM ***Introduction***

Marco Gottardis
Gottardisbiotech LLC

10:30 AM - 10:45 AM ***Novel Cell Therapy Platforms without Lymphodepletion for Solid Tumors***

David Fontana
Umoja Biopharma

10:45 AM - 10:50 AM **Discussion**

10:50 AM - 11:05 AM ***In Vivo Cell Engineering with Targeted Lipid Nanoparticles***

Priya Karmali
Capstan Therapeutics

11:05 AM - 11:10 AM **Discussion**

Saturday, October 26, 2024

11:10 AM - 11:25 AM ***Small Molecule Sequence-Selective Translation Inhibitors Inhibit the Growth of MYC-Driven Tumors by Target Deprivation***

Lawrence Hamann

Interdict Bio

11:25 AM - 11:30 AM **Discussion**

11:30 AM - 11:45 AM ***Synthetic Lethality in a Plastic Genome - Novel ecDNA Targeted Therapy Platform***

Christian Hassig

Boundless Bio

11:45 AM - 11:50 AM **Discussion**

Closing Remarks

11:50 AM - 11:55 AM


Howard Soule

Prostate Cancer Foundation

Andrea Miyahira

Prostate Cancer Foundation

Meeting Adjourned



Program Committee:

Program Committee Co-Chair: Howard Soule (Prostate Cancer Foundation)

Program Committee Co-Chair: Andrea Miyahira (Prostate Cancer Foundation)

Bissan Al-Lazikani (The University of Texas MD Anderson Cancer Center)

Isla Garraway (University of California, Los Angeles; Greater Los Angeles VA Healthcare System)

Andrew Goldstein (University of California, Los Angeles)

Marco Gottardis (Gottardisbiotech LLC)

Vanessa M. Hayes (The University of Sydney, Australia)

Michael Hofman (Peter MacCallum Cancer Centre, Australia)

Duygu Kuzuoglu Ozturk (University of California, San Francisco)

Alicia Morgans (Dana-Farber Cancer Institute)

Saul Priceman (University of Southern California)

Davide Ruggero (University of California, San Francisco)

Jelani Zarif (Johns Hopkins University)

Amina Zubeidi (University of British Columbia)

We deeply thank our Retreat supporters for providing funding for this educational initiative.



Actinium Pharmaceuticals, Inc.

